Acyclovir

DrugBank ID: DB00787

Summary

Metric	Value
Total Predictions	53
KG+DL (Dual Validated)	3
DL Only	47
KG Only	3

Predictions

Indication	Score	Source
chickenpox	0.9983	KG+DL
punctate epithelial keratoconjunctivitis	0.9967	DL
herpes zoster	0.9949	KG+DL
common wart	0.9946	DL
post-infectious neuralgia	0.9925	DL
hepatitis C induced liver cirrhosis	0.9923	DL
eosinophilic pustular folliculitis	0.9922	DL
sequela of COVID-19	0.9916	DL
vulvovaginal candidiasis	0.9911	DL
papular urticaria	0.9909	DL
disease of orbital region	0.9908	DL
epidemic keratoconjunctivitis	0.9907	DL
disease of orbital part of eye adnexa	0.9899	DL
cystic teratoma	0.9894	DL
spinal cord dermoid cyst	0.9891	DL
trigeminal autonomic cephalalgia	0.9887	DL
dermoid cyst of ovary	0.9883	DL
acanthoma (disease)	0.9881	DL
vulvar nodular hidradenoma	0.9878	DL
skin lymphangioma	0.9876	DL
skin hemangioma	0.9874	DL
syringofibroadenoma	0.9873	DL
trichoblastoma	0.9872	DL
breast apocrine adenoma	0.9868	DL
metastasis from malignant tumor of colon	0.9858	DL
strongyloidiasis	0.9856	DL
headache disorder	0.9855	DL
AIDS-related disorder	0.9855	DL
cervical dermoid cyst	0.9845	DL
non-human animal disease	0.9843	DL
genital herpes	0.9842	KG+DL
metastatic carcinoma	0.9831	DL
metastatic malignant neoplasm in the colon	0.9827	DL
metastatic malignant neoplasm in the spinal cord	0.9824	DL
ulcerative proctosigmoiditis	0.9822	DL
breast fibrocystic disease	0.9818	DL
scotoma (disease)	0.9816	DL
neurotrophic keratopathy	0.9806	DL
keratomalacia	0.9804	DL
ophthalmia nodosa	0.9804	DL
toxic maculopathy due to antimalarial drugs	0.9804	DL
visual snow syndrome	0.9804	DL
lacrimal apparatus disease	0.9804	DL
apocrine adenosis of breast	0.9801	DL
blunt duct adenosis of breast	0.9801	DL
keratoacanthoma	0.9799	DL
ocular vascular disease	0.9796	DL
IgG4-related ophthalmic disease	0.9793	DL
malignant pleural mesothelioma	0.9792	DL
plantar wart	0.9792	DL

Showing top 50 of 53 predictions.

External Links

Disclaimer
Predictions are for research purposes only and do not constitute medical advice.